We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+0.22%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.87B
AUM Growth
-$81.8M
Cap. Flow
+$153M
Cap. Flow %
5.32%
Top 10 Hldgs %
73.56%
Holding
37
New
4
Increased
20
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$84.9M
2
PCVX icon
Vaxcyte
PCVX
+$78.9M
3
RVMD icon
Revolution Medicines
RVMD
+$62.5M
4
JANX icon
Janux Therapeutics
JANX
+$59M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$54.3M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$84.6M
2
ARVN icon
Arvinas
ARVN
+$57.6M
3
IMVT icon
Immunovant
IMVT
+$38.9M
4
CGEM icon
Cullinan Oncology
CGEM
+$38.9M
5
MRUS
Merus
MRUS
+$36.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
26
Scholar Rock
SRRK
$5.61B
$17.3M 0.6%
+400,000
New +$13M
ORKA
27
Oruka Therapeutics
ORKA
$5.77B
$15.9M 0.55%
819,660
+100,000
+14% +$2.44M
AGIO icon
28
Agios Pharmaceuticals
AGIO
$1.83B
$9.08M 0.32%
+276,439
New +$13M
ACLX
29
CALL
DELISTED
Arcellx
ACLX
– –
-800,000
Closed -$66.8M
ARVN icon
30
Arvinas
ARVN
$596M
– –
-2,339,961
Closed -$57.6M
CATX icon
31
Perspective Therapeutics
CATX
$350M
– –
-919,692
Closed -$12.3M
CGEM icon
32
Cullinan Oncology
CGEM
$1.02B
– –
-2,321,013
Closed -$38.9M
CMPS
33
Compass Pathways
CMPS
$1.55B
– –
-1,160,000
Closed -$7.31M
IMVT icon
34
Immunovant
IMVT
$8.01B
– –
-1,362,827
Closed -$38.9M
KROS icon
35
Keros Therapeutics
KROS
$195M
– –
-525,037
Closed -$30.5M
KURA icon
36
Kura Oncology
KURA
$832M
– –
-4,331,321
Closed -$84.6M
PCVX icon
37
CALL
Vaxcyte
PCVX
$7.81B
– –
-276,800
Closed -$31.6M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return

Paradigm Biocapital Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Paradigm Biocapital Advisors held 37 positions worth $2.87B, down 2.8% from $2.96B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Paradigm Biocapital Advisors deployed $153M of net new capital in Q4 2024, opening 4 new positions and adding to 20 existing holdings. Its largest new stake was LENZ Therapeutics: 770,455 shares worth $22.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $36.7M trimmed.

  • Paradigm Biocapital Advisors's largest Q4 2024 buy was LENZ Therapeutics: 770,455 shares worth $22.2M.
  • Paradigm Biocapital Advisors added most to BeOne Medicines Ltd in Q4 2024, an estimated $84.9M increase.
  • Paradigm Biocapital Advisors's biggest Q4 2024 reduction was Merus, cutting an estimated $36.7M.
  • Paradigm Biocapital Advisors fully exited Kura Oncology in Q4 2024, selling an estimated $84.6M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 74% of its $2.87B portfolio in Q4 2024.
  • Paradigm Biocapital Advisors opened 4 new positions and closed 9 in Q4 2024.
  • Paradigm Biocapital Advisors's portfolio value fell 2.8% quarter-over-quarter to $2.87B.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.